All In Biotech

Drug Trial Radar · NCT03030612

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Dec 2016

Primary completion

Aug 2022

Study completion Aug 2022

Sponsor

Lead sponsor
OncoVerity, Inc.Industry
Sponsor type
Industry
Collaborators
argenx; Janssen Research & Development, LLC
First posted
Jan 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the maximum tolerated dose (MTD) of ARGX-110 and/or the recommended Phase II dose (RP2D) in combination with a standard dose of azacytidine (AZA) in Phase 1; and to evaluate efficacy of ARGX-110 when administered at a RP2D level established in Phase I in combination with a standard dose of AZA (proof-of concept) by evaluating overall response rate (ORR) in Phase 2.

Conditions

  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes

Interventions

  • ARGX-110Drug

    ARGX-110 will be administered intravenously.

  • AZADrug

    AZA will be administered subcutaneously/intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants with Dose Limiting Toxicity (DLT)Time frame: Up to 3.6 years
  2. Phase 2: Overall Response Rate (ORR)Time frame: Up to 3.6 years

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Marseille, France

  • Site not named

    Paris, France

  • Site not named

    Pierre-Bénite, France

  • Site not named

    Toulouse, France

  • Site not named

    Aarau, Switzerland

  • Site not named

    Bern, Switzerland

  • Site not named

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.